Effect of insulin angiotensin II receptor subtype-1 antagonist on myocardial remodelling in rats with insulin-dependent diabetes mellitus

Journal of Hypertension

Volumn 23, Issue 2, 2005, Pages 381-392

  Al Jaroudi, Wael A ^a   Nuwayri Salti, Nuha ^a   Usta, Julnar A ^a   Zwainy, Darine S ^a   Karam, Chehade N ^a   Bitar, Khalil M ^a   Bikhazi, Anwar B ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Angiotensin receptors; Cardiomyopathy; Insulin receptors; Insulin dependent diabetes mellitus; Losartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; IODINE 125; LOSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTERCOSTAL MUSCLE; MALE; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SKELETAL MUSCLE; WESTERN BLOTTING;

EID: 14044257224     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200502000-00021     Document Type: Article

References (32)

1. Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther 2000; 22:1186-1203.
2. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855-1864.
3. Berk BC. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol 1999; 10(suppl 11):S62-S68.
4. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, et al. Myocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest 2000; 80:513-527.
5. Dickstein K, Kjekshus J. Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (the OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 2001; 87:766-771.
6. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;m 359:995-1003.
7. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 358:1004-1010.
8. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortalilty in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587.
9. Brenner BM, Cooper ME, de Zeeuw DD, Keane WF, Mitch WE, Paving HH, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
10. Murali B, Goyal RK. Effect of chronic treatment with losartan on streptozotocin induced diabetic rats. Indian J Exp Biol 2002; 40:31-34.
11. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn RC. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93:12490-12495.
12. Chandramouli V, Carter JR Jr. Cell membrane changes in chronically diabetic rats. Diabetes 1975; 24:257-262.
13. Haddad RE, Jurjus AR, Ibrahim MZM. Nahlè ZA, El-Kasti MM, Bitar KM, et al. Binding of 125 I-insulin on capillary endothelial and myocytes cell membranes in normal and streptozotocin-induced diabetic rat hearts. Comp Biochem Physiol A Physiol 1997; 117:523-530.
14. Berthiaume N, Claing A, Regoli D, Warner TD, D'Orleans-Juste P. Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guinea-pig. Br J Pharmacol 1995; 115:1319-1325.
15. Bikhazi AB, Khalifeh AM, Jaroudi WA, Saadeddine RE, Jurjus AR, El-Sabban ME, et al. Endothelin-1 receptor subtypes expression and binding in a perfused rat model of myocardial infarction. Comp Biochem Physiol C Toxicol Pharmacol 2003; 134:35-43.
16. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87:1123-1132.
17. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 2001; 50:2363-2375.
18. de Mello WC, Danser AH. Angiotensin II and the heart: on the intracrine renin-angiotensin. Hypertension 2000; 35:1183-1188.
19. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, et al. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 1999; 107:133-139.
20. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn RC. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93:12490-12495.
21. Shannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002; 98:33-39.
22. Malhotra A, Penpargkul S, Fein FS, Sonnenblick EH, Scheuer J. The effect of streptozotocin induced diabetes in rats on cardiac contractile proteins. Circ Res 1981; 49:1243-1250.
23. Malhotra A, Reich D, Nakouzi A, Sanghi V, Greenen DL, Buttrick PM. Experimental diabetes is associated with functional activation of protein C epsilon and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade. Circ Res 1997; 81:1027-1033.
24. Wang P, Almahfouz A, Giorgino F, McCowen K, Smith R. In vivo insulin signaling in the myocardium of streptozotocin diabetic rats: opposite effects of diabetes on insulin stimulation of glycogen synthase and c-fos. Endocrinology 1999; 140:1141-1150.
25. Brownsey RW, Boone AN, Allard MF. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc Res 1997; 34:3-24.
26. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, et al. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 1999; 107:133-139.
27. Folli F, Kahn R, Hansen H, Bouchie J, Feener E. Angiotensin II inhibits signaling in aortic smooth muscle cells at multiple levels. J Clin Invest 1997; 100:2158-2169.
28. Kamide K, Hori M, Zhu J, Barrett J, Eggena P, Tuck M. Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998; 32:482-487.
29. Cui TX, Nakagami H, Nahmias C, Shiuchi T, Takeda-Matsubara Y, Li JM, et al. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC 12w cells. Mol Endocrinol 2002; 16:2113-2123.
30. Hoenack C, Roesen P. Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (GLUT 4) in diabetic rat heart. Diabetes 1996; 45(suppl 1):S82-S87.
31. Ishizawa K, Yoshizumi M, Tsuchiya K, Takishita E, Nakaya Y, Kishi K, et al. Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long Evans Tokushima Fatty rats. Eur J Pharmacol 2001; 430:359-367.
32. Bikhazi AB, Azar ST, Birbari AE, El-Zein GN, Haddad GE, Bitar KM. Characterization of insulin-resistance: role of receptor alteration in insulin-dependent diabetes mellitus, essential hypertension and cardiac hypertrophy. Eur J Pharm Sci 2000; 11:299-306.